Literature DB >> 2620460

Laboratory and clinical features of lactate dehydrogenase subunit deficiencies.

M Maekawa1, T Kanno.   

Abstract

Heterozygous subjects with lactate dehydrogenase (LD) subunit deficiencies do not always show a low serum LD activity. Thus, it is necessary to examine the serum and erythrocyte LD isozyme patterns when screening for these conditions. We assessed patients with heterozygotes for H and M subunit deficiency by immunoblotting with anti-H subunit antibody. We could not find any protein or variant proteins in the heterozygous subjects with M subunit deficiency. On the other hand, the existence of variant protein was confirmed in the heterozygous subjects with H subunit deficiency. However, in one patient with homozygous for H subunit deficiency, no H subunit protein was observed. It is suggested that possibly many types of LD subunit deficiency may exist. Only patients with homozygous for M subunit deficiency show common patterns of clinical findings. All patients with LD subunit deficiencies have the risk of misdiagnosis of other clinical conditions from laboratory data because LD release is reduced. Thus it is important to detect them as a latent hereditary symptom poor disorders recognizing in laboratory medicine.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2620460     DOI: 10.1016/0009-8981(89)90220-9

Source DB:  PubMed          Journal:  Clin Chim Acta        ISSN: 0009-8981            Impact factor:   3.786


  5 in total

1.  Dual targeting of the Warburg effect with a glucose-conjugated lactate dehydrogenase inhibitor.

Authors:  Emilia C Calvaresi; Carlotta Granchi; Tiziano Tuccinardi; Valeria Di Bussolo; Robert W Huigens; Hyang Yeon Lee; Rahul Palchaudhuri; Marco Macchia; Adriano Martinelli; Filippo Minutolo; Paul J Hergenrother
Journal:  Chembiochem       Date:  2013-10-31       Impact factor: 3.164

2.  Lactate dehydrogenase (LD), alkaline phosphatase (ALP) isoenzymatic patterns in Iraqi children with visceral leishmaniasis before and after treatment with stibogluconate.

Authors:  Jasim Hameed Taher; Yassir Mustafa Kamal Al-Mulla Hummadi; Nada Muhammed Taha Al-Bashir; Ali Shaalan Al-Araji
Journal:  J Parasit Dis       Date:  2014-06-22

3.  Hepatic Lactate Dehydrogenase A: An RNA Interference Target for the Treatment of All Known Types of Primary Hyperoxaluria.

Authors:  Gema Ariceta; Kelly Barrios; Bob D Brown; Bernd Hoppe; Ralf Rosskamp; Craig B Langman
Journal:  Kidney Int Rep       Date:  2021-02-03

4.  LDHA-Mediated Glycolytic Metabolism in Nucleus Pulposus Cells Is a Potential Therapeutic Target for Intervertebral Disc Degeneration.

Authors:  Longxi Wu; Jieliang Shen; Xiaojun Zhang; Zhenming Hu
Journal:  Biomed Res Int       Date:  2021-06-10       Impact factor: 3.411

5.  LDHA-mediated ROS generation in chondrocytes is a potential therapeutic target for osteoarthritis.

Authors:  Manoj Arra; Gaurav Swarnkar; Ke Ke; Jesse E Otero; Jun Ying; Xin Duan; Takashi Maruyama; Muhammad Farooq Rai; Regis J O'Keefe; Gabriel Mbalaviele; Jie Shen; Yousef Abu-Amer
Journal:  Nat Commun       Date:  2020-07-09       Impact factor: 14.919

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.